Underdog Pharmaceuticals, Inc. is a spin-off of SENS Research Foundation with the purpose of creating cyclodextrins to fight 7-ketocholesterol, a dangerous oxidated form of cholesterol that serves no useful purpose in the human body and that our macrophages cannot digest, leading to the formation of bloated foam cells and deadly atherosclerosis.
Underdog intends to use computational and synthetic chemistry to search through thousands of derivatives of cyclodextrin, a well-known and safe molecule, in order to discover one that is best at removing 7-ketocholesterol from blood vessels and cells.
Co-founded by Matthew O’Connor, Ph.D. and Michael Kope of SRF, the company has received nearly 4 million dollars in seed funding in order to begin operations. According to a June 2021 press release, Underdog launched a Series A funding round in which it sought to raise $9m. Underdog also successfully met with the Medicines and Health products Regulatory Agency (MHRA) of the UK to set the standards and endpoints of a phase 1 trial.